Methylation of the N 6 position of adenosine (m 6 A) is a posttranscriptional modification of RNA with poorly understood prevalence and physiological relevance. The recent discovery that FTO, an obesity risk gene, encodes an m 6 A demethylase implicates m 6 A as an important regulator of physiological processes.
INTRODUCTION
The fat mass and obesity-associated (FTO) gene is a major regulator of metabolism and energy utilization (Church et al., 2009 (Church et al., , 2010 Fischer et al., 2009) . In humans, FTO polymorphisms that increase FTO expression are associated with elevated body mass index and increased risk for obesity (reviewed in Fawcett and Barroso, 2010) . FTO is a member of the Fe(II)-and oxoglutarate-dependent AlkB oxygenase family and was originally shown to catalyze the oxidative demethylation of methylated thymidine and uracil (Gerken et al., 2007; Jia et al., 2008) . However, FTO exhibits low activity toward these base modifications, and they are relatively infrequent with unclear physiological relevance (Klagsbrun, 1973) . Thus, the physiologically relevant targets of FTO were unclear until recent studies that showed that FTO can demethylate N 6 -methyladenosine (m 6 A), a naturally occurring adenosine modification (Jia et al., 2011) . These studies link adenosine methylation to physiological roles in human biological processes. The distribution of m 6 A in RNA is poorly understood. Previous studies have found that m 6 A exists in RNA from a variety of unique organisms, including viruses, yeast, and mammals (Beemon and Keith, 1977; Bodi et al., 2010) . m 6 A is found in tRNA (Saneyoshi et al., 1969) , rRNA (Iwanami and Brown, 1968) , and viral RNA (Beemon and Keith, 1977; Dimock and Stoltzfus, 1977) . Although m 6 A is detectable in mRNA-enriched RNA fractions (Desrosiers et al., 1974) , it has been confirmed in vivo in only one mammalian mRNA (Horowitz et al., 1984) . The abundance of m 6 A has been shown to be 0.1%-0.4% of total adenosine residues in cellular RNA (Dubin and Taylor, 1975; Perry et al., 1975; Wei et al., 1975) , suggesting that this modification may be widespread throughout the transcriptome. Although the existence of m 6 A has been known for many years, progress in establishing the prevalence of m 6 A in mRNA has lagged behind that of other modified bases. This is due in large part to the lack of available methods for detecting the presence of m 6 A.
Because methylation of adenosine does not alter its ability to base pair with thymidine or uracil, m 6 A is not amenable to detection with standard hybridization or sequencing-based methods.
Here, we examine the prevalence, regulation, and functional roles of m 6 A in the transcriptome. We show that m 6 A is a developmentally regulated RNA modification that is dynamically modified. Using antibodies that recognize m 6 A, we have developed an affinity enrichment strategy that, when coupled with next-generation sequencing, allows for the high-throughput identification of m 6 A sites. Using this approach, we present the first transcriptome-wide profile of m 6 A localization in RNA. We find that m 6 A is a widespread modification that is present in the mRNAs of >7,600 genes and in >300 noncoding RNAs. Additionally, m 6 A is highly enriched near the stop codon and in the 3 0 UTR. Furthermore, bioinformatic analysis of m 6 A localization reveals consensus sites for m 6 A and identifies a potential interaction between m 6 A and microRNA pathways.
RESULTS

Detection of m 6
A in Mammalian mRNA Because m 6 A exhibits the same base pairing as unmodified adenosine, it is not readily detectable by standard sequencing or hybridization-based approaches. Additionally, m 6 A is not susceptible to chemical modifications that might otherwise facilitate its detection, such as bisulfite treatment, which is used to detect 5mC in DNA. The methods used thus far to detect m 6 A have involved treating cells with radiolabeled methionine, the precursor of the endogenous methylating agent S-adenosylmethionine, to impart radiolabeled methyl groups to adenosine (Csepany et al., 1990; Dubin and Taylor, 1975; Narayan and Rottman, 1988) . Radiolabeled m 6 A residues are subsequently mapped with thin-layer chromatography or HPLC. In order to simplify detection of m 6 A, we sought to develop an immunoblotting strategy. For these experiments, we used a previously described anti-m 6 A antibody (Bringmann and Lü hrmann, 1987; Jia et al., 2011; Munns et al., 1977) . To ensure the specificity of this antibody for m 6 A, we performed dot blots using modified oligonucleotides immobilized to a membrane. The m 6 A antibody selectively bound to oligonucleotides containing a single m 6 A residue and exhibited negligible binding to oligonucleotides containing unmodified adenosine ( Figure 1A ). The binding was competed by incubating the antibody with increasing concentrations of an m 6 A-rich competitor RNA (Figure 1B) . However, RNA containing unmodified adenosine did not compete for binding. Furthermore, binding was competed by N 6 -methyladenosine triphosphate, but not by ATP or other modified adenosine triphosphates, including N 1 -methyladenosine and 2 0 -O-methyladenosine ( Figure 1C ). Finally, to examine the specificity of the antibody in the context of other nucleotide sequences, we took advantage of the fact that the enzyme encoded by the DNA adenine methylase (dam) gene in E. coli methylates the N 6 position of adenosine in DNA. Upon subjecting digested DNA isolated from dam+ and dam-E. coli to immunoblotting using the m 6 A antibody, we found robust signals only in the DNA samples from the dam+ strain ( Figure 1D ). Collectively, these data demonstrate the high sensitivity and selectivity of this antibody for m 6 A, as well as its ability to detect m 6 A within cellular nucleotide pools.
To explore the abundance of m 6 A within various RNA populations, we isolated RNA from several mouse tissues and subjected it to immunoblot analysis using the m 6 A antibody (Figure 2A) . We found that m 6 A was present in all RNA samples tested, indicating that this modified nucleotide is widely distributed in many tissues, with particularly high enrichment in liver, kidney, and brain ( Figure 2B ). In addition, we observed large differences in the m 6 A content of various immortalized cell lines, including several cancer cell lines, which further indicates that large differences in m 6 A levels exist in different cell populations (Figure S1A available online). m 6 A immunoreactivity was detected in bands throughout the molecular weight range of the blot ($0.2 kb to $10 kb), consistent with incorporation of m 6 A in mRNA. Indeed, fractionation of whole cellular RNA into polyadenylated and nonpolyadenylated 
RNAs indicates that m 6
A immunoreactivity is enriched in the polyadenylated RNA pool, which further suggests that m 6 A in cellular RNA is localized to mature mRNA ( Figure 2C ). To determine whether m 6 A is present in poly(A) tails, we selectively removed the poly(A) tail from cellular mRNA using oligo(dT) hybridization and RNase H treatment. Transcripts depleted of the poly(A) tail did not exhibit an appreciable reduction in m 6 A levels ( Figure 2D ). In addition, immunoblotting poly(A) tails alone showed minimal m 6 A immunoreactivity ( Figures S2C-S2E ).
Together, these data demonstrate that m 6 A is primarily an internal modification that is largely absent from the poly(A) tail. Figure 3A) . A similar increase in m 6 A levels is also observed in RNA isolated from embryonic and postnatal rat brain cultured neurons ( Figure S1B ), which suggests that upregulation of m 6 A levels accompanies neuronal maturation.
We next asked whether adenosine methylation is a dynamically regulated posttranscriptional modification and whether its levels can be regulated by specific demethylating enzymes. In our search for potential demethylating enzymes that act to remove the methyl group from m 6 A, we focused on members of the family of Fe(II)-and 2-oxoglutarate-dependent oxygenases, several of which have previously been shown to demethylate both DNA and RNA (Falnes et al., 2007; Gerken et al., 2007) . Consistent with the findings of Jia et al. (2011) , we observed that FTO decreased m 6 A levels when overexpressed in mammalian cells ( Figure 3B ). Furthermore, we find that overexpression of FTO resulted in a broad size range of RNAs that exhibit reduced m 6 A immunoreactivity ( Figure 3B ).
MeRIP-Seq Identifies m 6
A-Containing RNAs throughout the Transcriptome In order to obtain insight into potential roles for m 6 A, we sought to characterize its distribution throughout the transcriptome. To do this, we first determined whether the m 6 A antibody could be used to enrich m 6 A-containing RNAs. In vitro immunoprecipitation experiments showed that a single round of MeRIP produces $70-fold enrichment, and two rounds produce >130-fold enrichment for m 6 A-containing targets ( Figure S3 ). To identify m 6 A sites throughout the transcriptome, we developed a method that combines m 6 A-specific methylated RNA immunoprecipitation (MeRIP) with next-generation sequencing (RNA-Seq). The procedure for MeRIP-Seq (outlined in Figure 4A ) involves randomly fragmenting the RNA to $100 nt sized fragments prior to immunoprecipitation. Because an m 6 A site could lie anywhere along the length of a given immunoprecipitated 100 nt fragment, sequencing reads are expected to map to a region that contains the m 6 A site near its center. At its extremes, this region would be predicted to be roughly 200 nt wide (100 nt up-and downstream from the m 6 A site) ( Figures 4B and 4C ). tail-depleted RNA (right) are comparable. Removal of poly(A) tails was confirmed using 3 0 RACE and RT-PCR to detect b-actin; no product is detected in the tail-depleted sample when oligo(dT) primers are used for cDNA synthesis (middle). As a control, use of random hexamers successfully generates a product in both samples (bottom). See also Figure S1 .
We next utilized MeRIP-Seq to identify m 6 A sites in total mouse brain RNA. Reads from the MeRIP sample frequently mapped to mRNAs and clustered as distinct peaks. As predicted, these peaks frequently converged to $100 nt wide regions near their midpoint ( Figure 4C ). Furthermore, enrichment of reads in these regions was not observed in the non-IP control sample, which was composed of the input RNA prior to m 6 A immunoprecipitation, demonstrating the specificity of these peaks ( Figure S3 ). To determine the location of these peaks throughout the transcriptome and thus characterize the regions of m 6 A localization, we developed an algorithm for identifying m 6 A peaks (see Extended Experimental Procedures). Additionally, we performed replicate MeRIP-Seq experiments in which we utilized: (1) a different sequencing platform (Illumina's GAIIx versus HiSeq2000), (2) independently prepared RNA samples from different animals, and (3) an unrelated m 6 A antibody (Kong et al., 2000) , which exhibited similarly high specificity for m 6 A ( Figure S4 ). We employed our algorithm to identify m 6 A peaks that met a minimum p value (p % 0.05, Benjamini and Hochberg corrected) within each individual sample. From the three samples, we identified a total of 41,072 distinct peaks in the RNAs of 8,843 genes, which we call our ''filtered'' set of m 6 A peaks (Table S1 ). Of these peaks, 80% were detected in at least two different replicates. The high concordance between these samples indicates that MeRIP-Seq is highly reproducible across different sequencing platforms and using different m 6 A antibodies. For subsequent bioinformatic analyses, we used the list of 13,471 m 6 A peaks in RNAs from 4,654 genes that were detected in all three replicates (our ''high-confidence'' list; Table  S2A ). This list demonstrates the presence of m 6 A in a substantial fraction of the transcriptome and indicates that m 6 A is a common feature of mammalian mRNAs. 
A Is Detected in Noncoding RNAs
The majority of our high-confidence m 6 A peaks (94.5%) are found within mRNAs. However, we also observed that 236
(1.8%) of our peaks mapped to noncoding RNAs (ncRNAs) that were annotated in the RefSeq database (Table S2A ). In addition, 588 m 6 A peaks did not map to a known RefSeq mRNA or ncRNA.
To determine whether these unannotated peaks localize to ncRNAs predicted in other databases, we aligned them to genomic regions of a set of 32,211 ncRNAs from the RIKEN functional annotation of mouse (FANTOM3) data set that we obtained from the mammalian noncoding RNA database (RNAdb; Pang et al., 2005) . We found that 216 of these peaks mapped to a FANTOM3 ncRNA (Table S2B ). All of these ncRNAs were >200 nt in length, indicating that long ncRNAs are substrates for adenosine methylation. Additionally, when we interrogated a set of conserved human lincRNAs (Cabili et al., 2011) for overlaps with m 6 A peaks, we found nine additional peaks that overlapped with these lincRNAs (Table S2C) . Collectively, these data identify several classes of ncRNAs as targets of adenosine methylation.
Biochemical Validation of m 6
A-Containing Transcripts We next sought to validate the presence of m 6 A in mRNAs identified with MeRIP-Seq. To do this, we used RNA pull-down assays to isolate individual mRNAs from total mouse brain RNA by hybridization to target-specific probes. Isolated mRNAs were then subjected to immunoblot analysis using the m 6 A antibody to detect the presence of m 6 A. Using this method, we validated the presence of m 6 A within low density lipoprotein receptor (Ldlr) ( Figures 5A and 5B), metabotropic glutamate receptor 1 (Grm1), and dopamine receptor D1A (Drd1a) ( Figures  S5A-S5D ). These mRNAs were chosen to demonstrate our ability to validate m 6 A presence in transcripts with multiple methylation sites (Grm1 and Drd1a) as well as those with single m 6 A peaks (Ldlr). To further demonstrate that MeRIP-Seq selectively enriches for these endogenous methylated targets, we performed qRT-PCR on the unbound fractions after RNA precipitation with the m 6 A antibody. As expected, we observed substantial immunodepletion of Grm1, Drd1a, and other methylated targets in the unbound fraction. In contrast, transcripts that lack m 6 A peaks, such as Rps21 and Ndel1, were detectable at high levels in the unbound fraction ( Figure S5E ).
A-Containing mRNAs Are Involved in Important Biological Pathways To predict potential signaling pathways and cellular processes that involve m 6 A, we used the DAVID bioinformatics database to identify the gene ontology (GO) terms that are enriched for m 6 A-containing transcripts. We found that genes encoding m 6 A-containing RNAs are involved in a variety of cellular functions, including transcriptional regulation, RNA metabolism, and intracellular signaling cascades (Table S5 ). In addition, we observed that m 6 A peaks mapped to many genes linked to neurodevelopmental and neurological disorders, such as Bdnf, Dscam, Lis1, and Ube3a, as well as the neurexins and several neuroligins. Collectively, these data demonstrate that m 6 Acontaining RNAs are involved in a variety of biological pathways that are relevant to cellular signaling and disease.
Because m 6
A is a physiological target of FTO, we sought to determine whether mRNAs whose levels have previously been shown to be influenced by FTO activity contain m 6 A. We A. See also Figure S1 . examined a list of 77 mRNAs whose levels are either up-or downregulated in the liver, skeletal muscle, or white adipose tissue of mice homozygous for a nonsynonymous FTO point mutation (Church et al., 2009) . mRNAs from seven genes that were significantly upregulated in FTO mutants (Acaca, Atf6, Bip, Gcdh, Irs1, Perk, and Xbp1) also contain m 6 A peaks. Intriguingly, some of these genes are involved in important metabolic pathways, raising the possibility that demethylation of the transcripts of these genes may contribute to the mechanism by which FTO regulates metabolism and energy homeostasis. (Table S3 ). Additionally, of the genes that contain more than one m A clustering is a common feature in methylated transcripts ( Figure S6A ). We also identified 68 genes that have long (R1 kb) stretches of contiguous m 6 A peaks (Table S4) A residues within the area covered by each peak. Therefore, the peaks with the highest levels of local m 6 A enrichment may represent a single adenosine residue that exhibits a high degree of methylation or multiple adjacent m 6 A residues with a lower stoichiometry of methylation. In either case, the high levels of methylation observed at these sites likely indicate transcripts that are most influenced by m 6 A-dependent regulatory processes. A peaks occur within intragenic regions ( Figure 5C ). These m 6 A peaks are abundant in coding sequences (CDS; 50.9%) and untranslated regions (UTRs; 41.9%), with relatively few in intronic regions (2.0%) ( Figure 5C ). Additionally, m 6 A peaks are less abundant in the 5 0 UTR (7.0% of UTR peaks) than in the 3 0 UTR (93.0% of UTR peaks) ( Figure 5C ). This distribution deviates substantially from the distribution of reads in the non-IP sample, indicating the high degree of enrichment of Figure 5C ). Although a low percentage of m 6 A peaks was observed in intronic regions, because our samples were not enriched for unspliced premRNAs, it is possible that additional methylated intronic sequences exist. We next sought to determine whether m 6 A peaks are preferentially found in certain portions of transcripts. To do this, we assigned each m 6 A peak to either a 5 0 UTR, CDS, or 3 0 UTR category and assigned it to 1 of 100 bins based on its location along the 5 0 UTR, CDS, or 3 0 UTR. These data show that m 6 A occurs at low levels in the 5 0 UTR and in the 5 0 end of the CDS. In the CDS, the percentage of m 6 A peaks increases steadily along transcript length and is, on average, 5-to 6-fold higher at the end of the CDS than at the beginning ( Figure 5D ). In the 3 0 UTR, the peaks are enriched near the stop codon and decrease in abundance along the length of the 3 0 UTR. Indeed, 61% of m 6 A peaks are in the first quarter of the 3 0 UTR, and a quarter of all m 6 A peaks across the entire transcriptome are found within the first 26% of the 3 0 UTR ( Figure 5D ). Mapping the number of m 6 A peaks 1 kb up-and downstream of CDS end sites further demonstrated the high levels of methylation in the vicinity of the stop codon ( Figures S7A and S7B) . Collectively, these data indicate that m 6 A peaks are highly clustered in the vicinity of the stop codon in mRNAs. Figure 6A ) and that m 6 A peaks' median conservation score (0.578) was much higher than that of the random regions (0.023). The fact that m 6 A frequently occurs in evolutionarily conserved sequences suggests that m 6 A-containing regions are maintained through selection pressure.
Because the tools for transcriptome-wide localization of m 6 A sites have until now been unavailable, only a few studies to date have examined the sequence contexts of m 6 A formation (Canaani et al., 1979; Dimock and Stoltzfus, 1977; Wei et al., 1976) . Using methods such as RNase T1 fingerprinting of radiolabeled RNA followed by separation by thin-layer chromatography, these studies reported that m 6 A exists within two unique sequence contexts: GAC and AAC (underlined adenosines indicate m 6 A). Subsequently, an extended m 6 A consensus sequence was identified: PuPuACX (Pu = purine; X = A, C, or U). However, because the methods used in these studies are not practical for use in a high-throughput manner, it is unclear whether these motifs are relevant to the transcriptome-wide m 6 A sites identified by MeRIP-Seq.
We therefore sought to identify sequence motifs that are enriched within m 6 A peaks. To do this, we used FIRE, a sensitive and unbiased tool for discovering RNA regulatory elements (Elemento et al., 2007 A peaks with the highest levels of enrichment. , chi-square test). Altogether, we found that >90% of all m 6 A peaks contain at least one of the motifs identified by FIRE. We next examined the position of the motifs within m 6 A peaks.
Nearly 30% of m 6 A peaks have only one motif ( Figure S6B ), indicating that these peaks are likely to contain only a single methylated residue. Motifs are also preferentially found in the center of m 6 A peaks ( Figures 6C and 6D ), suggesting that these peaks derive from a centrally located methylated adenosine residue. Of note, other RNA regulatory elements, such as AU-rich elements, poly(A) signals, or binding sites for known RNAbinding proteins, were not identified by FIRE, suggesting that m 6 A is unlikely to primarily function by modifying these known regulatory elements.
Relationship between m 6
A Sites and Polyadenylation Signals in 3 0 UTRs FIRE did not identify an enrichment of poly(A) signals (PASs), which are involved in 3 0 UTR end processing, in m 6 A peaks.
However, PASs exhibit considerable sequence heterogeneity beyond the canonical AAUAAA consensus (Tian et al., 2005) . This sequence heterogeneity might allow these PASs to evade detection by FIRE despite being enriched in m 6 A peaks.
Therefore, we sought to further investigate whether m 6 A peaks within 3 0 UTRs are enriched at PASs. We obtained a high-confidence list (Brockman et al., 2005) of poly(A) cleavage sites (the site downstream of a PAS where the mRNA is actually cleaved and polyadenylated) for the mRNAs that contain m 6 A peaks within their 3 0 UTRs. We then examined whether m 6 A peaks were enriched near these sites by determining the number of 3 0 UTR m 6 A peaks that fell within 50 nt upstream of each cleavage site. Because a PAS is located $10-30 nt upstream of an actual mRNA cleavage site (reviewed in Proudfoot, 1991) , these 50 nt long regions are expected to contain the PAS. Of the 6,288 m 6 A peaks found within 3 0 UTRs, 1,042 (16.6%) overlapped with the 50 nt long regions upstream of poly(A) cleavage sites, compared to 1,070 (17.0%) control peaks, which were generated from random nonoverlapping regions of the same 3 0 UTRs. Thus, these data suggest that m 6 A does not have a significant association with known PASs (p = 0.39; chi-square test).
A Is Not Enriched at Splice Junctions Prior studies that used nonspecific methylation inhibitors to explore possible functions for m 6 A revealed impaired splicing in a small number of RNAs (Carroll et al., 1990; Stoltzfus and Dane, 1982) . We therefore asked whether the localization of m 6 A peaks is compatible with a role for influencing the binding of splicing factors. However, only 80 splice junctions were found in regions contiguous with m 6 A peaks, significantly fewer than the overlap seen with a set of randomly generated peaks (9,531; p = 0.0; chi-square test). Thus, unlike CLIP-Seq tag clusters from RNA-binding proteins that influence splicing (Licatalosi et al., 2008) Figure 6E ). The reason for this inverse localization pattern is unknown, though it could indicate that a certain spatial separation is necessary for m 6 A to influence the function of a downstream-bound miRNA or vice versa. We next sought to determine whether miRNA-targeted transcripts in the brain are more likely to contain m 6 A. To test this, we used TargetScan to identify the target transcripts of the 25 most highly expressed and 25 least highly expressed miRNAs within the brain. Intriguingly, we observed that the most highly 0 UTR is also observed in other species. We therefore profiled m 6 A in HEK293T cells, a human cell line with high levels of adenosine methylation ( Figure 3B ). We generated a high-confidence list of m 6 A peaks using three MeRIP-Seq biological replicates and confirmed by both m 6 A antibodies. We found that the distribution of m 6 A peaks in HEK293T cells closely mirrored the distribution in mouse brain, with 31% and 53% of m 6 A peaks falling within the 3 0 UTR and the CDS, respectively ( Figures 5D and  S7D) . As with the pattern of m 6 A distribution in the mouse brain transcriptome, HEK293T m 6 A peaks were predominantly localized near stop codons ( Figures 5D and S7C ). In total, we identified 18,756 peaks in RNAs encoded by 5,768 genes in HEK293T cells (Table S6A) . Additionally, we found that transcripts from 2,145 and 3,259 genes were methylated only in the mouse brain and HEK293T data sets, respectively, and that transcripts from 2,509 genes were methylated in both data sets (Table S6B) . Interestingly, among the transcripts methylated in both tissues, m 6 A peaks were often localized to the same distinct regions of both orthologs ( Figure 5E A is a reversible and widespread modification that is primarily located in evolutionarily conserved regions and is particularly enriched near the stop codon. We also find that many features of m 6 A localization are conserved between the human and mouse transcriptomes, and we uncover a previously unidentified link between m 6 A and miRNA signaling. Collectively, these studies reveal that m 6 A is a widespread and dynamically regulated base modification in mRNA, and they identify mRNAs that are most likely to be influenced by signaling pathways that influence m 6 A levels.
One of the most striking features of m 6 A localization is its prevalence within 3 0 UTRs. The 3 0 UTR is an important region for RNA regulation, as it can influence RNA stability, subcellular localization, and translation regulation. Several of these events are regulated by RNA-binding proteins (RBPs) that bind to cis-acting structural motifs or consensus sequences within the 3 0 UTR and act to coordinate RNA processing. Conceivably, m 6 A may influence the affinity of specific RBPs for their target mRNAs, analogous to the recruitment of methyl-CpG-binding protein 2 (MeCP2) to methylated cytosine residues in DNA (Lewis et al., 1992) . Given the abundance of m 6 A throughout the transcriptome and its widespread localization, such a role for m 6 A would be likely to have important consequences for the regulation of numerous mRNAs. Our profiling of m 6 A in HEK293T cells revealed thousands of transcripts that are also methylated in the mouse brain. In many cases, the patterns of m 6 A localization within these transcripts are nearly identical, suggesting that some RNAs possess highly conserved methylation profiles. However, we also uncovered many transcripts that exhibit distinct cell-typespecific methylation patterns, demonstrating that m 6 A is also capable of being differentially regulated within unique cellular environments. Our finding that a large proportion of 3 0 UTRs that contain m 6 A peaks also contain miRNA binding sites is highly suggestive of an association between m 6 A and miRNA function. Additionally, our analysis indicated an inverse localization of m 6 A peaks and miRNA-binding sites within 3 0 UTRs, with m 6 A sites typically preceding, but not overlapping, the miRNA sites in the 3 0 UTRs. Although miRNAs can inhibit their target mRNAs by promoting either transcript degradation or translational repression (Guo et al., 2010; Hendrickson et al., 2009 ), the factors that determine which fate predominates are not well understood. Conceivably, the proximity of m 6 A to a miRNA-binding site could influence the mechanism of miRNA-mediated transcript inhibition. Additionally, it is possible that miRNA binding influences m 6 A levels within 3 0 UTRs. Indeed, our finding that abundant miRNAs are more significantly enriched in m 6 A peaks than weakly expressed miRNAs raises the possibility that miRNAs regulate methylation status.
A surprising result of these studies is the finding that m 6 A is highly enriched near stop codons. This recurrent localization within transcripts suggests that adenosine methylation in the vicinity of the stop codon may be of functional importance. Interestingly, the consensus for adenosine methylation is relatively short, and sequences that match the consensus are found throughout the transcriptome. However, despite the frequency of m 6 A consensus sites, methylation occurs primarily near stop codons. It will be important to determine how this specificity is achieved and whether cellular mechanisms that involve recognition of the stop codon or the beginning of the 3 0 UTR are involved in providing specificity to adenosine methylation.
The finding that FTO demethylates m 6 A suggests that misregulation of pathways controlled by adenosine methylation ultimately affect physiologic processes in humans. Although m 6 A is found in many classes of RNA, it is intriguing to speculate that FTO mutations mediate their effects by affected m 6 A in mRNA. Indeed, our finding that FTO can demethylate diverse mRNAs is consistent with this model. Direct characterization of m 6 A profiles in patients with FTO mutations will be useful to establish the mechanisms by which this mutation leads to disease. In summary, our study demonstrates that m 6 A is a widespread modification found in a large fraction of cellular mRNA. The pervasive nature of this epitranscriptomic modification suggests that adenosine methylation has important roles in RNA biology. Much in the way that cytosine methylation and hydroxymethylation in DNA are important epigenetic regulators of the genome, our data demonstrate that adenosine methylation in RNA is a reversible modification throughout the transcriptome that is likely to influence a wide variety of biological pathways and physiological processes.
EXPERIMENTAL PROCEDURES
MeRIP-Seq Total mouse brain RNA was subjected to RiboMinus treatment to reduce rRNA content as per the manufacturer's instructions (Invitrogen). RNA was then fragmented to 100 nt sized fragments using Illumina Fragmentation Buffer according to the manufacturer's instructions and was subjected to two rounds of m 6 A immunoprecipitation. Sequencing libraries were prepared using the Illumina protocol for mRNA samples, and sequencing was performed on an Illumina GAII3 or an Illumina HiSeq2000 as indicated. Genomic alignment (mm9 or hg19 from UCSC genome browser) was done using the Burrows-Wheeler Aligner (BWA) (Li and Durbin, 2010) at default settings, or using TopHat (see Extended Experimental Procedures). We analyzed only those reads that (1) uniquely mapped to the genome and (2) had a Phred quality score R20. Additional methods are detailed in the Extended Experimental Procedures.
ACCESSION NUMBERS
MeRIP-Seq data have been deposited in the GEO database under accession number GSE29714. 
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